All In Biotech

Drug Trial Radar · NCT05751798

Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas

A Multicenter, Phase 1/2, Dose-finding and Dose Expansion Study of OSE-279, a PD-1 Blocking Monoclonal Antibody, in Subjects With Advanced Solid Tumors or Lymphomas

Last checked: Nov 19, 2026Latest source record: Jun 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

41

Planned (sponsor's estimate)

Start

Dec 20, 2022

Primary completion

Dec 2029

Study completion Dec 2029

Sponsor

Lead sponsor
OSE ImmunotherapeuticsIndustry
Sponsor type
Industry
First posted
Mar 2, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 1/2, multicenter, dose-finding and dose expansion study of OSE-279, a PD-1 blocking monoclonal antibody, in subjects with advanced solid tumors or lymphomas.

Conditions

  • Solid Advanced Tumor
  • Lymphoma
  • NSCLC (Non-small Cell Lung Cancer)

Interventions

  • Part A: OSE-279 100mgDrug

    Human IgG4 mAb against PD-1

  • Part A: OSE-279 300mgDrug

    Human IgG4 mAb against PD-1

  • Part A: OSE-279 600mgDrug

    Human IgG4 mAb against PD-1

  • Part B: OSE-279 600 mg and OSE2101Drug

    OSE-279: OSE-279: Human IgG4 mAb against PD-1 OSE2101: Cancer vaccine

  • Part C: OSE-279 600 mg and OSE2101 - HLA-A2 positiveDrug

    OSE-279: Human IgG4 mAb against PD-1 OSE2101: Cancer vaccine

  • Part C: OSE-279 600 mg - HLA-A2 positifDrug

    OSE-279: Human IgG4 mAb against PD-1

  • Part C: OSE-279 600 mg - HLA-A2 negativeDrug

    OSE-279: Human IgG4 mAb against PD-1

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Occurrence of dose limiting toxicity (DLT). Part B: Safety and tolerability of the combination OSE-279/OSE2101. Part C: Overall response rate (ORR) of the combination OSE-279/OSE2101Time frame: Part A: DLT observation period is defined as the first 21 days after receiving the 1st injection of OSE-279 (Cycle 1) Part B: DLT observation period is defined as the first 6 weeks after receiving the combinaison Part C: Best response

Locations

11 sites in 3 countries. Site status is shown where the registry gives one.

  • Institut Jules Bordet

    Anderlecht, Belgium · Recruiting

  • Antwerp University Hospital

    Edegem, Belgium · Recruiting

  • Centre Léon Bérard

    Lyon, France · Recruiting

  • Hopital Saint Joseph

    Paris, France · Recruiting

  • Centre Eugène Marquis

    Rennes, France · Completed

  • Institut de Cancerologie de l'Ouest

    Saint-Herblain, France · Recruiting

  • Oncopole

    Toulouse, France · Recruiting

  • Institut Gustave Roussy

    Villejuif, France · Recruiting

  • University Hospital A Coruña Biomedical Research Institute (INIBIC)

    A Coruña, Spain · Recruiting

  • Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta (IDIBGI)

    Girona, Spain · Recruiting

  • Hospital Regional Universitario de Málaga

    Málaga, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.